Genmab technology

Genmab uses the patented UltiMAb® transgenic mouse technology platform to create monoclonal HuMab® antibodies from transgenic mice. The antibodies produced by the transgenic mice are completely human and can be rapidly generated. Specific antibodies can be selected based on desired binding properties and mechanism of action. Genmab has extensively optimized and automated the process of antibody generation and characterization of HuMab® antibodies, to allow the efficient selection of the best antibody product candidates.

Back to top

Monoclonal antibodies bind to their target molecule via two identical and highly specific binding regions, located on the tips of both arms of the antibody. In bispecific antibodies, the two binding regions are not identical, and each region is directed against a different molecule or different site (epitope) on the same molecule. By binding two different molecules instead of one, bispecific antibodies can bind even more specifically to a certain target cell, or can connect a target cell with a white blood cell that will kill the target cell.

Genmab has developed its own proprietary platform for bispecific antibody generation, DuoBody technology. The DuoBody platform is an innovative platform for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. Bispecific antibodies bind to two different epitopes either on the same, or on different targets (also known as dual-targeting) which may improve the antibodies’ specificity and efficacy in inactivating the disease target cells. DuoBody molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies, which allows DuoBody molecules to be administered and dosed as other antibody therapeutics. Genmab's DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench as well as commercial manufacturing scale.

To read more about the DuoBody platform, visit DuoBody.com. To read a white paper on the DuoBody technology published in PNAS, click here.

Back to top

The HexElect®; antibody platform is Genmab’s new novel proprietary technology, which combines two HexaBody molecules designed to effectively and selectively hit only those cells that express both targets. The HexElect platform maximizes potency while minimizing potential toxicity, potentially leading to more potent and safer products.

Back to top

Antibody-drug conjugates (ADC) represent a new development for cancer immunotherapy. ADCs are monoclonal antibodies with potent toxic agents coupled to them. By using antibodies that recognize specific targets on tumor cells, these toxic agents are preferentially delivered to these cells. In this way, only malignant cells will be killed leaving the healthy cells intact. Genmab has entered into an antibody-drug conjugate research collaboration agreement with Seattle Genetics concerning Genmab’s product: tisotumab vedotin.

Back to top

The HexaBody platform is Genmab's novel proprietary technology designed to increase the potency of antibodies. Antibodies have a natural ability to eliminate pathogens and tumor cells by various cytotoxic mechanisms. The HexaBody platform strengthens the killing ability of antibodies while retaining regular structure and specificity. The technology has the potential to enhance antibody therapeutics for a broad range of applications in cancer and infectious diseases.

Back to top